Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are currently recommended as the initial injectable treatment for patients with type 2 diabetes (T2D) who did not achieve adequate control with oral glucose-lowering medications [1]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.